ProKidney Corp. is a late clinical stage biotechnology company focused on developing autologous cell therapies to preserve kidney function in patients with advanced chronic kidney disease and type 2 diabetes. The company's lead product candidate, rilparencel, consists of a patient's own selected renal cells that are expanded outside the body and re injected into the kidney via a minimally invasive outpatient procedure. By using autologous cells, rilparencel avoids the need for lifelong immunosuppression required after allogeneic kidney transplantation. The therapy is designed to stabilize or slow the decline of estimated glomerular filtration rate, a key measure of kidney function. According to the company, chronic kidney disease affects over 37 million people in the United States, with more than one million of those patients suffering from moderate to severe disease and type 2 diabetes and representing the initial target population.

ProKidney Corp. does not currently generate revenue from product sales because rilparencel remains in clinical development. The company intends to generate future revenue through the commercial sale of rilparencel after obtaining regulatory approval. It anticipates addressing a significant unmet need by offering a therapy that could delay or prevent kidney failure in the targeted patient group. Until approval, the company finances its operations primarily through equity offerings and related financing activities, and may also pursue licensing agreements or collaborations that provide additional income.

Within the biotechnology sector focused on kidney disease, ProKidney Corp. occupies a niche as one of the few companies advancing an autologous cell based therapy for chronic kidney disease. Its primary competitors include manufacturers of established pharmacologic agents such as SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), mineralocorticoid receptor antagonists (e.g., finerenone), and GLP 1 receptor agonists (e.g., semaglutide, tirzepatide) that are used to slow CKD progression. The company differentiates itself by using a personalized approach that utilizes the patient’s own kidney cells, thereby eliminating the need for immunosuppression. Rilparencel has received regenerative medicine advanced therapy designation from the U. S. Food and Drug Administration, which is intended to expedite development and review. Additionally, the therapy is designed for administration in an outpatient setting, offering a potential convenience advantage over chronic dialysis or surgical transplantation.

ProKidney Corp.'s intended customers are patients suffering from moderate to severe chronic kidney disease who also have type 2 diabetes, as well as the nephrologists, dialysis centers, and hospitals that treat this population. The company has not yet disclosed specific customer names because the product is not commercially available. Should rilparencel receive approval, the company expects to serve both private and public healthcare providers across the United States and potentially in international markets where it pursues regulatory clearance.